Mg2+ dependence of halothane-induced Ca2+ release from the sarcoplasmic reticulum in skeletal muscle from humans susceptible to malignant hyperthermia

Anesthesiology

Volumn 101, Issue 6, 2004, Pages 1339-1346

  Duke, Adrian M ^a   Hopkins, Philip M ^b   Halsal, Jane P ^b   Steele, Derek S ^a  

^a UNIVERSITY OF LEEDS   (United Kingdom)

^b ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM; FURA 2; HALOTHANE; MAGNESIUM; RYANODINE RECEPTOR; CAFFEINE; CENTRAL STIMULANT AGENT; INHALATION ANESTHETIC AGENT; RYANODINE;

ARTICLE; CALCIUM TRANSPORT; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DISEASE PREDISPOSITION; HUMAN; HUMAN TISSUE; MALIGNANT HYPERTHERMIA; MUSCLE CELL; PERFUSION; PRIORITY JOURNAL; SARCOPLASMIC RETICULUM; SKELETAL MUSCLE; VASTUS MEDIALIS MUSCLE; CYTOSOL; DRUG EFFECT; IN VITRO STUDY; METABOLISM; PHYSIOLOGY;

ANESTHETICS, INHALATION; CAFFEINE; CALCIUM; CENTRAL NERVOUS SYSTEM STIMULANTS; CYTOSOL; HALOTHANE; HUMANS; MAGNESIUM; MALIGNANT HYPERTHERMIA; MUSCLE FIBERS; MUSCLE, SKELETAL; RYANODINE; SARCOPLASMIC RETICULUM;

EID: 9444288134     PISSN: 00033022     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000542-200412000-00014     Document Type: Article

References (33)

1. 2+ regulation defects. Physiol Rev 1996; 76:537-92
2. Fujii J, Otsu K, Zorzato F, De Leon S, Khanna VK, Weiler JE, O'Brien PJ, MacLennan DH: Identification of a mutation in porcine ryanodine receptor associated with malignant hyperthermia. Science 1991; 253:448-51
3. Levitt RC, Dickers A, Meyers S, Fletcher JE, Rosenberg H, Isaacs H, Meyers DA: Evidence for the localization of a malignant hyperthermia susceptibility locus (MHS2) to human chromosome 17q. Genomics 1992; 14:562-6
4. Monnier N, Procaccio V, Stieglitz P, Lunardi J: Malignant-hyperthermia susceptibility is associated with a mutation of the alpha(1)-subunit of the human dihydropyridine-sensitive 1-type voltage-dependent calcium-channel receptor in skeletal muscle. Am J Hum Genet 1997; 60:1316-25
5. Robinson RL, Monnier N, Wolz W, Jung M, Reis A, Nuernberg G, Curran JL, Monsieurs K, Stieglitz P, Heytens L, Flicker R, vanBroeckhoven C, Deufel T, Hopkins PM, Lunardi J, Mueller CR: A genome wide search for susceptibility loci in three European malignant hyperthermia pedigrees. Hum Mol Genet 1997; 6:953-61
6. Sambuughin N, Sei Y, Gallagher KL, Wyre HW, Madsen D, Nelson TE, Fletcher JE, Rosenberg H, Muldoon SM: North American malignant hyperthermia population: Screening of the ryanodine receptor gene and identification of novel mutations. ANESTHESIOLOGY 2001; 95:594-9
7. Ohnishi ST, Waring AJ, Fang SR, Horiuchi K, Flick JL, Sadanaga KK. Ohnishi T: Abnormal membrane properties of the sarcoplasmic reticulum of pigs susceptible to malignant hyperthermia: Modes of action of halothane, caffeine, dantrolene, and two other drugs. Arch Biochem Biophys 1986; 247:294-301
8. Mickelson JR, Gallant EM, Litterer LA, Johnson KM, Rempel WE, Louis CF: Abnormal sarcoplasmic reticulum ryanodine receptor in malignant hyperthermia. J Biol Chem 1988; 263:9310-5
9. Wappler F, Anetsedec M, Baur CP, Censier K, Doetsch S, Felleiter P, Fiege M, Fricker R, Halsall PJ, Hartung E, Heffron JJ, Heytens L, Hopkins PM, Klingler W, Lehmann-Horn F, Nivoche Y, Tegazzin V, Tzanova I, Urwyler A, Weisshorn R, Schulte am EJ: Multicentre evaluation of in vitro contracture testing with bolus administration of 4-chloro-m-cresol for diagnosis of malignant hyperthermia susceptibility. Eur J Anaesthesiol. 2003; 20:528-36
10. 2+, and adenine-nucleotides. Biochemistry 1986; 25:236-44
11. Laver DR, Baynes TM, Dulhunty AF: Magnesium inhibition of ryanodine-receptor calcium channels: evidence for two independent mechanisms. J Membr Biol 1997; 156:213-29
12. 2+ releasing action of caffeine and depolarisation in skeletal muscle fibres of the rat. J Physiol 2001; 531:715-28
13. 2+ release in muscle fibres of pigs susceptible to malignant hyperthermia. Am J Physiol 1997; 272:203-11
14. 2+ release channels in malignant hyperthermia. Biophys J 1997; 73:1913-24
15. 2+ release in skeletal muscle from humans susceptible to malignant hyperthermia. J Physiol 2002; 544:85-95
16. Yang T, Ta TA, Pessah IN, Allen PD: Functional defects in six ryanodine receptor isoform-1 (RyR1) mutations associated with malignant hyperthermia and their impact on skeletal excitation-contraction coupling. J Biol Chem 2003; 278:25722-30
17. 2+ release from the sarcoplasmic reticulum in rat skeletal muscle. J Physiol 2003; 551:447-54
18. Nadler JL, Malayan S, Luong H, Shaw S, Natarajan RD, Rude RK: Intracellular free magnesium deficiency plays a key role in increased platelet reactivity in type II diabetes mellitus. Diabetes Care 1992; 15:835-41
19. The European Malignant Hyperpyrexia Group: A protocol for the investigation of malignant hyperpyrexia (MH) susceptibility. Br J Anaesth 1984; 56:1267-9
20. Ording H, Brancadoro V, Cozzolino S, Ellis FR, Glauber V, Gonano EF, Halsall PJ, Hartung E, Heffron JJ, Heytens L, Kozak-Ribbens G, Kress H, Krivosic-Horber R, Lehmann-Horn F, Mortier W, Nivoche Y, Ranklev-Twetman E, Sigurdsson S, Snoeck M, Stieglitz P, Tegazzin V, Urwyler A, Wappler F: In vitro contracture test for diagnosis of malignant hyperthermia following the protocol of the European MH Group: Results of testing patients surviving fulminant MH and unrelated low-risk subjects. The European Malignant Hyperthermia Group. Acta Anaesthesiol Scand 1997; 41:955-66
21. 2+. J Physiol 1990; 420:337-53
22. 2+ regulation by the sarcoplasmic reticulum in saponin permeabilized skeletal muscle fibres. Pflugers Arch 1998; 436:104-11
23. Franks NP, Lieb WR: Temperature dependence of the potency of volatile general anesthetics: Implications for in vitro experiments. ANESTHESIOLOGY 1996; 84:716-20
24. Davies DN, Steward A, Allott PR, Mapleson WW: A comparison of arterial and arterialized venous concentrations of halothane. Br J Anaesth 1972; 44:548-50
25. 2+ release in skeletal muscle fibres of the toad. J Physiol 1991; 434:507-28
26. 2+] on excitation-contraction coupling in skeletal muscle fibres of the rat. J Physiol 1994; 478(pt 2):331-9
27. 2+ inhibition and malignant hyperthermia. J Muscle Res Cell Motil 1993; 14:554-6
28. Yang T, Ta TA, Pessah IN, Allen PD: Functional defects in six RyR1 mutations associated with malignant hyperthermia and their impact on skeletal E-C coupling. J Biol Chem 2003; 28:25722-30
29. Haigney MC, Wei S, Kaab S, Griffiths E, Berger R, Tunin R, Kass D, Fisher WG, Silver B, Silverman H: Loss of cardiac magnesium in experimental heart failure prolongs and destabilizes repolarization in dogs. J Am Coll Cardiol 1998; 31:701-6
30. +-pump concentration in skeletal muscle. Acta Physiol Scand 1996; 156:305-11
31. Rodman JS: Hypermagnesemia and progression of renal failure (letter). Clin Nephrol 1986; 26:314
32. Dorman BH, Sade RM, Burnette JS, Wiles HB, Pinosky ML, Reeves ST, Bond BR, Spinale FG: Magnesium supplementation in the prevention of arrhythmias in pediatric patients undergoing surgery for congenital heart defects. Am Heart J 2000; 139:522-8
33. 2+] in malignant hyperthermia susceptible swine. ANESTHESIOLOGY 1990; 73:109-17